Randomized Control Trial: Heated Humidity High Flow Nasal Cannula in Comparison with NCPAP in the Management of RDS in Extreme Low Birth Infants in Immediate Post Extubation Period

Elkhwad M*, Dako JA, Jennifer G, Harriet F and Anand K
Division of Neonatology, Department of Pediatrics, Akron Children Hospital, Akron, Qatar

*Corresponding author: Elkhwad M, Division of Neonatology, Department of Pediatrics, Akron Children Hospital, Akron, Qatar, Tel: 330-5438352; E-mail: khwad2000@hotmail.com

Received date: January 17, 2017, Accepted date: January 22, 2017, Published date: January 30, 2017

Abstract

Background: Respiratory failure in neonates remains a difficult challenge and is associated with high morbidity and mortality. Current practice reflects the belief that limited exposure to invasive mechanical ventilation and careful use of oxygen support, results in less lung injury and improved long term pulmonary outcomes in preterm infants. Respiratory Distress Syndrome (RDS) is a common cause of respiratory failure in preterm infants and occurs in most preterm infants less than 28 weeks gestation. Standard of care involves surfactant administration and providing respiratory support.

Objective: To compare the primary outcome, failure of extubation defined by the need for re-intubation and mechanical ventilation within 5 days of initial extubation and secondary outcomes, morbidities and mortality after using of heated humidity high flow nasal cannula (HHHFNC) and Nasal Continuous Positive Airway Pressure (NCPAP) in the immediate post-extubation period for preterm infants between 24 and 28 weeks gestation with respiratory distress syndrome.

Methods: 60 preterm infants with gestational ages between 24 and 28 weeks were randomized in this study to either HHHFNC or NCPAP. The primary outcome measured was failed extubation defined by the need for re-intubation and mechanical ventilation within 5 days of initial extubation after receiving at least 2 doses of surfactant. Secondary outcome measures included: 1. Duration of respiratory support using HHHFNC/NCPAP. 2. Duration of oxygen requirement. 3. Incidence of complications i.e. Nasal breakdown, Sepsis, Intraventricular hemorrhage, Retinopathy of prematurity and Patent Ductus Arteriosis. Preterm infants who remained intubated for more than 24 hours were excluded from the study.

Results: 17.2% of neonates placed on HHHFNC failed extubation and required re-intubation within 5 days of initial extubation compared with 20.8% of neonates placed on NCPAP (p value 1.000). Mean duration of respiratory support using HHHFNC was 37.45 days compared with 40.04 days using NCPAP (p value 0.66). Duration of oxygen requirement for infants placed on HHHFNC was 49.41 days compared with 43.75 days for infants placed on NCPAP (p value 0.58). 25% of infants placed on NCPAP suffered nasal trauma, 12.5% developed sepsis, 12.5% had grades III and IV IVH, 41.67% were reported to have a PDA and 41.67% were reported to have varying stages of ROP. No nasal trauma was reported for infants placed on HHHFNC, 3.5% developed sepsis, 13.79% had grades III and IV IVH, 31.03% were reported to have a PDA and 24.14% were reported to have varying stages of ROP.

Conclusion: HHHFNC use is comparable to the use of NCPAP in the immediate post-extubation period for preterm infants between 24 and 28 weeks gestations with Respiratory Distress Syndrome without an increased risk for co-morbid conditions.

Keywords: NCPAP, HHHFNC; ELBW; RDS; Extubation

Background

The use of NCPAP as a method of respiratory support was first described in 1971 by Gregory, et al. [1] and has been proven to be an effective alternative to mechanical ventilation when needed [2]. It has been shown to improve oxygenation and decrease the rate of Chronic Lung Disease (CLD) and duration of oxygen therapy in neonates with physiologic benefits such as maintaining lung volume, lowering upper airway resistance and reducing obstructive apnea [3]. Heated humidity high flow nasal cannula (HHHFNC) is a newer method of respiratory support that has been introduced in recent years for respiratory support in neonates [4]. It delivers high flow humidified oxygen utilizing a simple nasal cannula to provide positive pressure ventilation and has been used with the assumption of comparable respiratory support with conventional NCPAP [4]. In spite of the lack of large randomized control studies HHHFNC has been widely accepted for use in neonatal units in some developed countries such as the United Kingdom and the United States [5].

HHHFNC appears to have a number of advantages over NCPAP including reduction in number of ventilator days and nasal trauma. It
has been suggested that NCPAP is associated with increased handling as a result of mechanical difficulties in appropriate fixation of prongs resulting in increased agitation and higher risk of sepsis and pneumothoraces [7,8]. In addition, there is an increased risk of sepsis due to the connection with a water source which is a potential source of contamination [9,10]. However, recent studies failed to show an increased risk of sepsis with the use of Vapotherm with the added advantage of improved growth associated with its use [11].

The purpose of this randomized controlled trial to study, if there is difference between HHHFNC and nCPAP in preventing extubation failure when applied as noninvasive respiratory support modes for neonates with respiratory dysfunction.

Methods

Study design and oversight

The study was approved by the Institutional Review Board of Akron Children's Hospital and informed consent was obtained for each patient. In this randomized controlled study, we prospectively compared the use of HHHFNC and NCPAP in the immediate post-extubation period for preterm infants between 24 and 28 weeks gestations with Respiratory Distress Syndrome.

Patients

Sixty preterm infants with gestational ages between 24 and 28 weeks admitted to the Akron Children's Hospital NICU from July 5, 2009 to April 16, 2012 were enrolled in the study and randomly assigned to NCPAP or HHHFNC post-extubation following administration of surfactant.

Inclusion criteria were:
- Preterm neonates with gestational age of 24 to 28 completed weeks.
- In the case of twins, both neonates were included in the same treatment arm.
- Success to wean with 24 hours to extubate.
- Parental written informed consent for participation in the study obtained on admission into the hospital or prior to delivery.

Exclusion criteria were:
- Evidence of severe birth asphyxia.
- Known genetic or chromosomal disorders.
- Infants delivered to mothers with ruptured membranes of more than three weeks duration.
- Potentially life-threatening conditions unrelated to prematurity.
- Participation in another clinical trial of any placebo, drug, biological, or device conducted under the provisions of a protocol.

Randomization

A computer-generated block-randomization sequence with random block sizes was used. Infants who were part of multiple births underwent individual randomization. Clinicians opened consecutively numbered, sealed, brown envelopes immediately before extubation to determine the study-group assignment.

Our NICU current practice

At delivery the decision as to whether a baby failed to respond to CPAP requiring intubation and surfactant was made by the attending neonatologist based on the consideration of respiratory distress, metabolic acidosis and increased oxygen requirement or apnea.

All extreme low birth infants who require intubation for severe RDS and respiratory failure will receive surfactant and then weaned of mechanical ventilation as tolerated with the aim to extubate them within the first 24 hours of life. Infants who will also receive intravenous loading dose of caffeine 20 mg per kilogram of body weight before extubation and then continue on maintenance dose of 10 mg per kilogram. These babies then will be placed on bubble CPAP and weaned off thereafter.

Study intervention

We used Tri-Anim Vapotherm the Precision Flow, which is a self-contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified. For NCPAP, we used Fisher and Paykel Healthcare, Bubble CPAP System. Babies assigned to NCPAP received bubble NCPAP at 5cmH2O and those assigned to HHHFNC received a flow rate up to 5L/min with increases of NCPAP to 6cmH2O at the discretion of the neonatologist.

The primary outcome measured was failed extubation defined by the need for re-intubation and mechanical ventilation within five days of initial extubation after receiving at least two doses of surfactant. The decision to extubate any baby after successfully weaning to minimal setting on Invasive Mechanical Ventilation (IMV) was made solely by the attending neonatologist as is current practice. Infants were deemed to have failed extubation if they demonstrated apnea with greater than one apneic episode requiring Positive Pressure Ventilation (PPV) within one hour or greater than two apneic episodes requiring PPV within eight hours; oxygen requirement >40%; increasing respiratory distress with pCO2 >60 and pH <7.2.

Secondary outcome measures investigated were: 1) Duration of respiratory support using HHHFNC/NCPAP. 2) Duration of oxygen requirement. 3) Incidence of nasal breakdown, sepsis, intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP) and patent ductus arteriosis (PDA).

Definitions

The gestational age was based on maternal dates. Ballard physical examination was used if the dates and physical examination determinations differed by more than two weeks. Grade III or IV IVH diagnoses were based on head ultrasound results. Presence of PDA was based on echocardiogram findings. Retinopathy of prematurity (ROP) is diagnosed per pediatric ophthalmologist. Sepsis was defined as a positive culture result from blood with concomitant clinical symptoms. Positive cultures were defined as having positive growth from the cerebrospinal fluid, tracheal, blood, or urine specimens (Table 1).
Demographics

<table>
<thead>
<tr>
<th></th>
<th>Bubble CPAP (n=24)</th>
<th>Vapotherm (n=29)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestation age (wks) mean (SD)</td>
<td>26.71 (0.95)</td>
<td>26.76 (0.095)</td>
</tr>
<tr>
<td>Birth Weight (grams) mean (SD)</td>
<td>995.33 (201.66)</td>
<td>994.54 (202.82)</td>
</tr>
<tr>
<td>Gender, n%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>14 (58.33)</td>
<td>15 (51.72)</td>
</tr>
<tr>
<td>Female</td>
<td>10 (41.67)</td>
<td>14 (48.28)</td>
</tr>
<tr>
<td>Race, n%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>13 (54.17)</td>
<td>20 (68.97)</td>
</tr>
<tr>
<td>Black</td>
<td>8 (33.33)</td>
<td>7 (24.14)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1 (4.17)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>Other</td>
<td>2 (8.33)</td>
<td>2 (6.90)</td>
</tr>
<tr>
<td>APGAR 1, mean (SD)</td>
<td>3.25 (2.51)</td>
<td>5 (2.43)</td>
</tr>
<tr>
<td>APGAR 5, mean (SD)</td>
<td>6.38 (2.00)</td>
<td>6.62 (2.00)</td>
</tr>
<tr>
<td>APGAR 10, mean (SD)</td>
<td>6.25 (2.19)</td>
<td>7.17 (1.19)</td>
</tr>
<tr>
<td>Mechanical ventilation (h) mean (SD)</td>
<td>19.21 (3.89)</td>
<td>19.45 (2.26)</td>
</tr>
<tr>
<td>Prenatal Steroids, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>16 (66.67)</td>
<td>26 (89.66)</td>
</tr>
<tr>
<td>No</td>
<td>8 (33.33)</td>
<td>3 (10.34)</td>
</tr>
</tbody>
</table>

Table 1: Characteristics of the study infants.

Currently there is no agreed upon classification available to describe the severity of nasal trauma secondary to nasal application of noninvasive apparatus in neonates. We therefore, used the standardized classification of the decubitus lesions from the US National Pressure Ulcer Advisory Panel (NPUAP) [12,13] to document our nasal trauma stages.

Stage I: erythema not blanching, on an otherwise intact skin.
Stage II: superficial ulcer or erosion, with partial thickness skin loss.
Stage III: necrosis, with full thickness skin loss.

Statistical analysis

Charts were reviewed and data was analyzed using SAS 9.2 based on primary and secondary outcome measures. To identify differences between the arms of the study, univariate analysis was performed using Student's t test (continuous data) or the X2 test (categorical variables) accordingly. Mann-Whitney U nonparametric tests were used in the presence of non-normal data. Statistical testing assumed an alpha significance level of 5%, thus statistical significance was defined as \( p \leq 0.05 \). Odds ratio (OR) and 95% confidence interval (CI) were calculated for each 2 × 2 table. All analyses were performed on an intention to- treat basis, and infants remained in their assigned group for all outcomes.

Results

Study patients

Sixty preterm infants with gestational ages between 24 and 28 weeks admitted to the Akron Children's Hospital NICU from July 5, 2009 to April 16, 2012 were enrolled in the study and randomly assigned to NCPAP or HHHFNC post-extubation following administration of surfactant.

Figure 1: Study flowchart for enrollment and outcomes.

Six babies met exclusion criteria and were excluded from the study, failed to be extubated within 24 hours of birth (Figure 1). One infant expired on day of life 24, for causes not related to the study and was not included in the final results. Data was available for 53 patients where 24 received NCPAP and 29 received HHHFNC (Figure 1).
As shown in Table 1, the average birth weight for infants in both groups was comparable at 950 grams, as well as gestational age of 26 weeks. There was no statistically significant difference regarding race, gender, prenatal steroids or Apgars scores between the two groups.

**Primary outcome**

HHHFNC use found to be comparable to the use of NCPAP. As shown in Table 2, Mean duration of respiratory support was 6.5% lower using HHHFNC rather than NCPAP, 37.45 ± 23.12 (SD) vs. 40.04 ± 19.21 days. Neonates on NCPAP required less oxygen than those on HHHFNC, 43.75 ± 34.21 (SD) vs. 49.41 ± 39.68 days. But that was not statistically significant between the oxygen required for the two modes (p=0.58).

**Secondary outcomes and adverse events**

There was no statistically significant relationship between the mode of post-extubation and the need for mechanical ventilation within 5 days of initial extubation (p=1.000) as shown on Table 2. However, a lower percentage of neonates on HHHFNC failed extubation and required re-intubation within 5 days of initial extubation than neonates on NCPAP, 17.2% vs. 20.8%.

### Table 2: Morbidities by ventilation method (n=53).

<table>
<thead>
<tr>
<th>Measure</th>
<th>Bubble CPAP, mean, SD</th>
<th>Vapotherm, mean, SD</th>
<th>Mean Difference (95% CL)</th>
<th>t value (df=8)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxygen Requirement</td>
<td>43.75 (34.21)</td>
<td>49.41 (39.68)</td>
<td>-5.66 (-26.33,15.00)</td>
<td>-0.55</td>
<td>0.58</td>
</tr>
<tr>
<td>Respiratory support</td>
<td>40.04 (19.21)</td>
<td>37.45 (23.12)</td>
<td>2.59 (-9)</td>
<td>0.44</td>
<td>0.66</td>
</tr>
</tbody>
</table>

### Table 3: Secondary outcomes of the study infants.

As shown in Table 3, 25% of neonates on NCPAP suffered nasal trauma whereas no nasal trauma was reported for neonates on HHHFNC. Table 4 shows this relationship was statistically significant (p=0.006). More neonates on NCPAP developed sepsis, 12.5% vs. 3.5% but this result was not statistically significant (p=0.318). 41.67% of neonates on NCPAP were reported to have a PDA vs. 31.03% of neonates on HHHFNC. More neonates on NCPAP than on HHHFNC had varying stages of ROP, 41.67% vs. 24.14%.

### Table 3: Secondary outcomes of the study infants.
Discussion

Ventilation induced lung injury in very low birth weight infants is associated with increased morbidity, including increased susceptibility to infection and chronic lung disease [14-16]. Among extremely low-birth-weight infants born at centers in the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network between 1993 and 1997, immaturity was the leading cause of early death and pulmonary conditions was the predominated cause of death for those surviving for late death [17]. Changes in neonatal care since this period, including changes in prenatal use of glucocorticoids and antibiotic agents, use of surfactants, and ventilation strategies may have led to a relative decrease in deaths attributable to pulmonary causes [18].

As a consequence, many centers encourage the use of non-invasive ventilation, primarily NCPAP as a mode of ventilation for neonates with RDS, following surfactant administration. In recent times, high flow humidified oxygen appears to be increasingly used compared with NCPAP as a result of perceived benefits which have not been convincingly proven [5].

In a survey done by Ojha et al. demonstrated that H HHHFNC is a widely used modality in UK neonatal units, and 34 units of the 44 who responded use the module. 39% units used Vapotherm without decreased nasal trauma.

Table 4: Association of ventilation Mode and morbidities.

<table>
<thead>
<tr>
<th>Association</th>
<th>Statistic</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Association between ventilation Mode and need for mechanical ventilation within 5 days of extubation</td>
<td>Fisher's Exact</td>
<td>1</td>
</tr>
<tr>
<td>Association between ventilation Mode and intraventricular hemorrhage grade</td>
<td>Fisher's Exact</td>
<td>1</td>
</tr>
<tr>
<td>Association between ventilation Mode and Retinopathy of Prematurity grade</td>
<td>Fisher's Exact</td>
<td>0.6</td>
</tr>
<tr>
<td>Association between ventilation Mode and associated diagnosis of Patent Ductus Arteriosis</td>
<td>Chi sq (df=1)</td>
<td>0.422</td>
</tr>
<tr>
<td>Association between ventilation Mode and associated diagnosis of sepsis</td>
<td>Fisher's Exact</td>
<td>0.318</td>
</tr>
<tr>
<td>Association between ventilation Mode and associated diagnosis of nasal breakdown</td>
<td>Fisher's Exact</td>
<td>0.006*</td>
</tr>
</tbody>
</table>

Conclusion

There is no significant difference between the use of HHHFNC and NCPAP in the immediate post-extubation period for preterm infants between 24 and 28 week gestations with Respiratory Distress Syndrome. More studies are needed to establish this finding and perhaps a multi-institutional study will be a beneficial next step in order to capture a larger sample size.

Financial Disclosure Statement

All authors have no interests relevant to the topic discussed in the submitted manuscript.
References


